Center For Cancer Targeted Therapies
-
Study seeks to boost breast tumor immune response
Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer. Read MoreFeb 8, 2018
-
Investigators match novel cancer mutations with potential therapies
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. Read MoreAug 3, 2017
-
Arteaga to direct UT Southwestern cancer center
Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas. Read MoreJul 13, 2017
-
VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’
Justin Balko, Pharm.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been named a member of the 2016 class of Pink Tie Guys by the Greater Nashville Affiliate of Susan G. Komen, a nonprofit organization dedicated to breast cancer research and patient support. Read MoreDec 10, 2015
-
VICC debuts new Center for Cancer Targeted Therapies
Vanderbilt-Ingram Cancer Center leaders formally dedicated the space for the new Center for Cancer Targeted Therapies (CCTT), located in the Infusion Center on the second floor of The Vanderbilt Clinic, at a special ribbon-cutting held during last week’s fall meeting of the Cancer Center’s Board of Overseers. Read MoreOct 31, 2013